55 related articles for article (PubMed ID: 12174895)
1. Enhancement of circulating dendritic cell activity by immunomodulators (OK432 and KP-40).
Toyokawa H; Inaba M; Takai S; Satoi S; Beuth J; Ko HL; Matsui Y; Kwon AH; Kamiyama Y; Ikehara S
Anticancer Res; 2002; 22(4):2137-45. PubMed ID: 12174895
[TBL] [Abstract][Full Text] [Related]
2. Early activation markers of human peripheral dendritic cells.
Hellman P; Eriksson H
Hum Immunol; 2007 May; 68(5):324-33. PubMed ID: 17462499
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of immunomodulators for maturation of dendritic cells.
Ogihara T; Iinuma H; Okinaga K
Int J Oncol; 2004 Aug; 25(2):453-9. PubMed ID: 15254744
[TBL] [Abstract][Full Text] [Related]
4. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
5. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity.
Naito K; Ueda Y; Itoh T; Fuji N; Shimizu K; Yano Y; Yamamoto Y; Imura K; Kohara J; Iwamoto A; Shiozaki A; Tamai H; Shimizu T; Mazda O; Yamagishi H
Int J Oncol; 2006 Jun; 28(6):1481-9. PubMed ID: 16685449
[TBL] [Abstract][Full Text] [Related]
6. Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells.
Teleshova N; Jones J; Kenney J; Purcell J; Bohm R; Gettie A; Pope M
J Leukoc Biol; 2004 Jun; 75(6):1102-10. PubMed ID: 15075365
[TBL] [Abstract][Full Text] [Related]
7. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
Koide T; Iinuma H; Fukushima R
Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients.
Ferrari S; Malugani F; Rovati B; Porta C; Riccardi A; Danova M
Oncol Rep; 2005 Jul; 14(1):113-20. PubMed ID: 15944777
[TBL] [Abstract][Full Text] [Related]
9. Cross-regulation of CD86 by CD80 differentially regulates T helper responses from Mycobacterium tuberculosis secretory antigen-activated dendritic cell subsets.
Balkhi MY; Latchumanan VK; Singh B; Sharma P; Natarajan K
J Leukoc Biol; 2004 May; 75(5):874-83. PubMed ID: 14966193
[TBL] [Abstract][Full Text] [Related]
10. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.
Sokolovska A; Hem SL; HogenEsch H
Vaccine; 2007 Jun; 25(23):4575-85. PubMed ID: 17485153
[TBL] [Abstract][Full Text] [Related]
11. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
Nakahara S; Tsunoda T; Baba T; Asabe S; Tahara H
Cancer Res; 2003 Jul; 63(14):4112-8. PubMed ID: 12874015
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
You J; Wang CL; Hao XS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
[TBL] [Abstract][Full Text] [Related]
17. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
[TBL] [Abstract][Full Text] [Related]
18. Impaired circulating myeloid DCs from myeloma patients.
Do TH; Johnsen HE; Kjaersgaard E; Taaning E; Svane IM
Cytotherapy; 2004; 6(3):196-203. PubMed ID: 15203976
[TBL] [Abstract][Full Text] [Related]
19. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
20. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.
Sharma S; Stolina M; Yang SC; Baratelli F; Lin JF; Atianzar K; Luo J; Zhu L; Lin Y; Huang M; Dohadwala M; Batra RK; Dubinett SM
Clin Cancer Res; 2003 Mar; 9(3):961-8. PubMed ID: 12631593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
